A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)
Condition(s) studied
Investigational drug(s) / intervention(s)
TAK-360: TAK-360 tablet
Placebo: TAK-360 matching placebo tablet
Study summary
Narcolepsy is a sleep disorder that disrupts a person's regular sleep-wake cycle. It causes extreme sleepiness during the day (called excessive daytime sleepiness \[EDS\]), where a person may fall asleep without warning. Narcolepsy Type 1 (NT1) is a form of the condition in which people also have sudden, unexpected muscle weakness while staying conscious (called cataplexy).
The main aim of this study is to learn how safe TAK-360 is and how well adults with NT1 tolerate it. Adults who can participate in the study will have to stop taking their existing medicines for NT1 before study treatment starts. Participants may be randomly (by chance, like drawing names from a hat) assigned to get either TAK-360 or placebo during the treatment period. The placebo looks just like TAK-360 but does not have any medicine in it. After the treatment period, participants can be monitored for another 2 weeks. Participants can restart their usual NT1 treatment after study treatment ends.
The participants will have to visit the clinic multiple times during this study.
Eligibility
Primary outcome measure(s)
- Parts A, B and C: Number of Participants With at Least One Treatment-emergent Adverse Events (TEAEs) — Up to approximately 28 weeks
An adverse event (AE) is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of the trial intervention, whether or not the occurrence is considered related to the trial intervention. A TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product.
Trial sites (18)
| Facility | City | Region | Status |
|---|---|---|---|
| Takeda Site 12 | Redwood City | California | Not Yet Recruiting |
| Takeda Site 14 | Miami | Florida | Recruiting |
| Takeda Site 13 | Cincinnati | Ohio | Recruiting |
| Takeda Site 2 | Macquarie Park | New South Wales | Not Yet Recruiting |
| Takeda Site 4 | Beijing | Beijing Municipality | Recruiting |
| Takeda Site 3 | Guangzhou | Guangdong | Recruiting |
| Takeda Site 5 | Zhengzhou | Henan | Recruiting |
| Takeda Site 6 | Herault | Montpelier | Not Yet Recruiting |
| Takeda Site 7 | Paris | France | Not Yet Recruiting |
| Takeda Site 8 | Bologna | Emilia-Romagna | Not Yet Recruiting |
| Takeda Site 9 | Verona | Veneto | Not Yet Recruiting |
| Takeda Site 17 | Fukuoka | Fukuoka | Recruiting |
| Takeda Site 1 | Kumamoto | Kumamoto | Recruiting |
| Takeda Site 18 | Isahaya-shi | Nagasaki | Recruiting |
| Takeda Site 15 | Yodogawa-ku, Osaka-shi | Osaka | Not Yet Recruiting |
| Takeda Site 16 | Shinjuku-ku | Tokyo | Recruiting |
| Takeda Site 11 | Barcelona | Spain | Not Yet Recruiting |
| Takeda Site 10 | Madrid | Spain | Not Yet Recruiting |
More Takeda trials in Japan
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07633301 on ClinicalTrials.gov ↗ ← All trials in Japan